Qiagen (NYSE:QGEN) Releases Q1 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its first quarter earnings guidance on Monday morning. The company provided EPS guidance of at least $0.55 for the period, compared to the consensus EPS estimate of $0.49. The company issued revenue guidance of ~$483 million, compared to the consensus revenue estimate of $464.42 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Analyst Ratings Changes

Several brokerages have weighed in on QGEN. Morgan Stanley restated an “equal weight” rating and set a $46.67 target price (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Robert W. Baird lowered Qiagen from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $52.00 to $42.00 in a research note on Wednesday, February 19th. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. UBS Group cut their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $52.50 price target (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Eight equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Qiagen has an average rating of “Hold” and a consensus target price of $47.71.

Qiagen Stock Down 5.3 %

Qiagen stock opened at $38.24 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The firm’s 50 day moving average price is $40.27 and its two-hundred day moving average price is $41.94. The firm has a market cap of $8.50 billion, a PE ratio of 106.48, a P/E/G ratio of 2.39 and a beta of 0.62.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. On average, research analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.